Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The ...

Trey Martin, CEO of Maravai LifeSciences, expressed confidence in the potential advancements the acquisition could bring, stating their intention to evolve Molecular Assemblies' workflows.

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

Canadian Pacific Kansas City (CPKC) today said that it has reached a tentative four-year collective agreement with the Teamsters Canada Rail Conference Maintenance of Way Employees Division (TCRC-MWED ...

Zai Lab Limited today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate ...

Marvai LifeSciences has acquired assets and intellectual property from Molecular Assemblies at undisclosed terms. Marvai, a San Diego company, said Tuesday that the acquisition would expand the ...

EST Maravai Lifesciences (MRVI) jumps 6% to $5.85 after MAI IP acquisition announcementInvest with Confidence: Follow TipRanks' Top Wall ...

Maravai LifeSciences has a 1-year low of $4.28 and a 1-year high of $11.56. The company has a market capitalization of $1.34 billion, a P/E ratio of -3.24 and a beta of -0.07. Get Maravai ...

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

Maravai LifeSciences has a 12 month low of $4.28 and a 12 month high of $11.56. The stock has a fifty day moving average price of $5.59 and a 200-day moving average price of $7.40. Maravai ...

Maravai LifeSciences Holdings, Inc. announced that it expects total revenue for 2024 to align with its previous guidance range of $255 million to $265 million based on preliminary year-end results ...